Infant and High-risk Children RSV Prevention Program
For the 2025/2026 respiratory season, infants and high-risk children will continue to be eligible for publicly funded Beyfortus® (Nirsevimab), or AbrysvoTM in pregnancy, to protect young children from severe RSV disease. Full details are available in the Ministry of Health Infant and High-risk Children Respiratory Syncytial Virus (RSV) Prevention Program Factsheet for Health Care Providers. The program launches Oct. 1, 2025.
Eligibility for Beyfortus® (Nirsevimab) (preferred product for infant protection):
- Infants born April 1, 2025, or after AND less than eight months of age up to the end of the RSV season (March 31, 2026).
- High-risk children up to 24 months of age who remain vulnerable from severe RSV disease through their SECOND RSV season*, with:
- Chronic lung disease (CLD), including bronchopulmonary dysplasia (BPD)/chronic lung disease
- Note: Children who were less than 12 months of age and approved for coverage in the previous RSV season for CLD and BPD remain eligible, irrespective of their clinical status in the second RSV season.
- Hemodynamically significant cyanotic or acyanotic congenital heart disease
- Severe immunodeficiency
- Down syndrome/Trisomy 21
- Cystic fibrosis with respiratory involvement and/or growth delay
- Neuromuscular disease impairing the clearing of respiratory secretions
- Severe congenital airway anomalies impairing the clearing of respiratory secretions
*These children are eligible even if they received Beyfortus® (Nirsevimab) during their first RSV season.
Eligibility for AbrysvoTM in Pregnancy:
- Pregnant individuals from 32 to 36 weeks gestational age if they will deliver prior to or during RSV season (generally from November 1 to March 31, peaking in December), in consultation with their health-care provider.
- If the vaccine (AbrysvoTM) is given during pregnancy, the monoclonal antibody (Beyfortus® [Nirsevimab]) is NOT recommended to be given to the infant except under specific circumstances:
- Infants born less than 14 days after administration of AbrysvoTM
OR
- Infants who meet the medical criteria for increased risk of severe RSV disease:
- All premature infants (i.e., < 37 weeks gestation)
- Newborns who meet any of the above "high-risk" criteria
RSV vaccine ordering
Health-care providers can submit their vaccine orders using routine channels (fax or email). All RSV orders should be submitted using this form.
- Order what you can administer in the next two weeks.
Please note, these products have large packaging and do require additional fridge space. - Do not batch order. If needed, reorder on a weekly basis.
- Do not order enough product for the whole season. See point #2 above.
- Beyfortus® 100mg comes in two package formats (i.e. single and five pack). We will fill orders based on what we receive.
